Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/2/2024	Chase Investment Counsel Corp	61,097	$0.27M	0.1%	N/A	0.051%
2/8/2024	Vanguard Personalized Indexing Management LLC	17,575	$69K	0.0%	-13.2%	0.016%
2/6/2024	a16z Perennial Management L.P.	79,869	$0.32M	0.0%	N/A	0.073%
1/11/2024	Naples Global Advisors LLC	10,000	$39K	0.0%	-50.0%	0.009%
12/6/2023	Citigroup Inc.	509,165	$0.87M	0.0%	-78.1%	0.462%
11/13/2023	FMR LLC	8,060,939	$13.70M	0.0%	-18.9%	7.344%
11/9/2023	Citigroup Inc.	509,165	$0.87M	0.0%	-78.1%	0.464%
11/8/2023	Vanguard Personalized Indexing Management LLC	20,243	$34K	0.0%	N/A	0.018%
10/27/2023	Marquette Asset Management LLC	43,028	$73K	0.0%	N/A	0.039%
10/27/2023	Acuitas Investments LLC	208,579	$0.36M	0.2%	N/A	0.190%
10/16/2023	Naples Global Advisors LLC	20,000	$34K	0.0%	N/A	0.018%
8/14/2023	683 Capital Management LLC	4,000,000	$4.20M	0.3%	+17.6%	3.644%
8/14/2023	Shay Capital LLC	87,395	$92K	0.0%	+91.9%	0.080%
8/10/2023	Citigroup Inc.	2,327,146	$2.44M	0.0%	+187,270.9%	2.126%
7/24/2023	BML Capital Management LLC	134,696	$0.14M	0.1%	N/A	0.123%
6/1/2023	Prelude Capital Management LLC	25,308	$30K	0.0%	N/A	0.023%
5/16/2023	Slate Path Capital LP	3,735,000	$4.48M	0.2%	N/A	3.417%
5/16/2023	Bain Capital Life Sciences Investors LLC	1,937,207	$2.33M	0.3%	N/A	1.772%
5/15/2023	Maverick Capital Ltd.	1,887,527	$2.27M	0.1%	N/A	1.727%
5/11/2023	Alphabet Inc.	5,680,785	$6.82M	0.4%	N/A	5.196%
5/3/2023	Triatomic Management LP	25,800	$31K	0.0%	N/A	0.024%
4/27/2023	Strs Ohio	24,300	$29K	0.0%	N/A	0.022%

Data available starting January 2016

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $2.42

$2.39

$2.54

50 Day Range

MA: $3.28

$2.07

$4.44

52 Week Range

Now: $2.42

$0.98

$5.20

Volume

345,458 shs

Average Volume

894,055 shs

Market Capitalization

$288.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Who are the company insiders with the largest holdings of Invivyd?: Invivyd's top insider investors include:
Adimab, Llc (Major Shareholder)
Learn More about top insider investors at Invivyd.
Who are the major institutional investors of Invivyd?: Invivyd's top institutional shareholders include:
Chase Investment Counsel Corp — 0.05%
Learn More about top institutional investors of Invivyd stock.
Which major investors are buying Invivyd stock?: Within the previous quarter, IVVD stock was purchased by institutional investors including:
Chase Investment Counsel Corp